Jasper van Grunsven, Senior Vice President of Amgen's Rare Disease Business Unit, had spent the week hearing directly from many of the advocates in the room. During a fireside conversation, he reflected on how quickly the boundaries between individual diseases can begin to blur when the discussion turns to what patients experience.

For advocacy organizations, much of that territory is familiar. They are often the ones helping families make sense of a new diagnosis, connecting people to resources, raising awareness where little exists, and pushing against barriers that can feel much larger than the communities confronting them.

Bringing those organizations together creates an opportunity for hard-earned experience to travel.

An approach developed in one disease community may help another think differently about diagnosis. A solution to an access challenge can offer a starting point elsewhere. Sometimes, simply hearing how another organization approached a problem can change the questions being asked back home.

That exchange has begun taking shape through efforts such as SPAARK, Amgen Rare Disease's Strengthening Partnerships to Advance Autoimmune Rare Knowledge initiative. SPAARK aims to cut the time to diagnosis in half for rare autoimmune diseases in the next ten years. Early conversations among participating advocacy organizations have highlighted the value of working together across disease areas, creating opportunities to combine their experience, perspectives, and influence to advance shared priorities and achieve greater collective impact.

For van Grunsven, that kind of partnership is fundamental to what progress in rare disease will require.

The Rare Disease Summit offered a glimpse of what that can look like in practice. Expertise did not sit with one speaker, company, or organization. It was present throughout the room, carried by advocates who had learned from patients, built programs around unmet needs, navigated setbacks, and arrived with knowledge that someone sitting a few chairs away might be able to use.

Before everyone headed home, there was one more opportunity to put that collaboration to work.

Advocates across several of Amgen's rare therapeutic areas—thyroid eye disease, generalized myasthenia gravis, IgG4-related disease, and uncontrolled gout—gathered in dedicated breakout sessions. After days spent looking across healthcare and rare disease, the focus turned toward the people each organization knows best.

The breakout sessions shifted the conversation from broad themes to practical priorities. Each advocacy community explored the issues most relevant to their patients—from strengthening the patient voice in access discussions and accelerating diagnosis and awareness to shaping future advocacy priorities and considering how emerging technologies could support patient care.

It was a fitting final turn for a gathering that had encouraged advocates to look beyond the boundaries of their own work. The value of hearing from another community is ultimately realized when an idea becomes useful somewhere else.

The week in Thousand Oaks had an ending. The work waiting at home did not.

Soon, everyone would do exactly that—go home.

Back to organizations, colleagues, families, and patient communities. Back to work that brought many of them to Thousand Oaks in the first place, but now carrying new relationships, different perspectives and perhaps another person to call when the next difficult question arrives.

The inaugural Rare Disease Summit gave the community a room of its own within Amgen's largest-ever advocacy gathering.

What matters now is what leaves the room with them.